Table 4.
Transplantation outcomes: MVA
| RELAPSE |
NRM |
LFS |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| sAML | 0.68 (0.47-1) | .051 | 1.38 (0.96-1.98) | .083 | 0.99 (0.76-1.28) | .94 |
| Patient age (per 10 y) | 0.92 (0.84-1.02) | .11 | 1.39 (1.19-1.62) | <.0001 | 1.06 (0.98-1.15) | .13 |
| Adverse risk group | 1.95 (1.49-2.55) | <.0001 | 0.97 (0.67-1.39) | .85 | 1.47 (1.18-1.82) | 5.00E−04 |
| First relapse vs PR | 0.98 (0.75-1.29) | .89 | 0.94 (0.67-1.33) | .72 | 0.95 (0.77-1.18) | .65 |
| KPS ≥ 90 | 0.69 (0.53-0.89) | .005 | 0.52 (0.37-0.73) | .0001 | 0.62 (0.5-0.76) | <.0001 |
| HCT-CI ≥ 3 | 1.03 (0.75-1.42) | .83 | 1.21 (0.85-1.73) | .29 | 1.12 (0.88-1.42) | .36 |
| PBSC vs BM | 1.14 (0.86-1.53) | .36 | 1.54 (1.04-2.27) | .032 | 1.26 (1-1.6) | .052 |
| RIC vs MAC | 1.03 (0.78-1.36) | .82 | 1.25 (0.88-1.79) | .22 | 1.14 (0.91-1.41) | .25 |
| Female donor to male recipient | 0.94 (0.69-1.27) | .68 | 0.96 (0.66-1.4) | .84 | 0.96 (0.75-1.21) | .72 |
| Patient CMV pos. | 1.17 (0.83-1.63) | .37 | 1.39 (0.91-2.15) | .13 | 1.24 (0.95-1.61) | .12 |
| Donor CMV pos. | 1.25 (0.94-1.67) | .13 | 0.89 (0.63-1.24) | .48 | 1.09 (0.87-1.35) | .45 |
| Year of HCT | 0.96 (0.92-1.01) | .15 | 0.97 (0.91-1.04) | .4 | 0.97 (0.93-1.01) | .15 |
| OS |
GRFS |
aGVHD grade 2-4 |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| sAML | 0.99 (0.77-1.29) | .97 | 0.99 (0.77-1.27) | .94 | 0.69 (0.43-1.11) | .13 |
| Patient age (per 10 y) | 1.09 (1.01-1.19) | .034 | 1.06 (0.98-1.15) | .12 | 1.01 (0.89-1.15) | .87 |
| Adverse risk group | 1.42 (1.14-1.77) | .002 | 1.29 (1.05-1.59) | .015 | 0.9 (0.62-1.31) | .6 |
| First relapse vs PR | 0.93 (0.75-1.16) | .53 | 0.94 (0.76-1.15) | .52 | 0.88 (0.62-1.26) | .49 |
| KPS ≥ 90 | 0.62 (0.5-0.76) | <.0001 | 0.62 (0.5-0.75) | <.0001 | 1.27 (0.88-1.81) | .2 |
| HCT-CI ≥ 3 | 1.13 (0.89-1.44) | .32 | 1.06 (0.85-1.34) | .59 | 0.84 (0.55-1.27) | .4 |
| PBSC vs BM | 1.23 (0.97-1.56) | .086 | 1.34 (1.06-1.68) | .013 | 1.64 (1.07-2.53) | .024 |
| RIC vs MAC | 1.17 (0.94-1.46) | .16 | 1.03 (0.84-1.27) | .76 | 1.14 (0.79-1.65) | .47 |
| Female donor to male recipient | 1 (0.79-1.28) | .98 | 1.03 (0.82-1.3) | .79 | 0.85 (0.56-1.28) | .44 |
| Patient CMV pos. | 1.33 (1.01-1.75) | .042 | 1.17 (0.91-1.51) | .23 | 0.9 (0.58-1.38) | .62 |
| Donor CMV pos. | 1.05 (0.84-1.31) | .65 | 1.07 (0.87-1.32) | .5 | 1.45 (0.99-2.13) | .056 |
| Year of HCT | 0.98 (0.94-1.02) | .42 | 0.98 (0.94-1.02) | .29 | 0.96 (0.9-1.02) | .19 |
| aGVHD grade 3-4 |
cGVHD |
Extensive cGVHD |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| sAML | 0.93 (0.47-1.85) | .84 | 1.39 (0.87-2.22) | .17 | 1.13 (0.6-2.15) | .7 |
| Patient age (per 10 y) | 0.98 (0.81-1.2) | .88 | 1 (0.87-1.15) | 1 | 1.2 (0.97-1.47) | .095 |
| Adverse risk group | 0.52 (0.27-0.99) | .045 | 0.71 (0.45-1.12) | .14 | 0.96 (0.54-1.72) | .9 |
| First relapse vs PR | 0.88 (0.52-1.48) | .62 | 0.85 (0.57-1.25) | .4 | 1.1 (0.65-1.86) | .72 |
| KPS ≥ 90 | 0.93 (0.56-1.56) | .8 | 0.75 (0.51-1.09) | .13 | 0.71 (0.43-1.18) | .18 |
| HCT-CI ≥ 3 | 0.88 (0.48-1.62) | .68 | 1.02 (0.66-1.59) | .92 | 1.01 (0.55-1.85) | .98 |
| PBSC vs BM | 2.49 (1.29-4.79) | .006 | 1.43 (0.95-2.15) | .086 | 1.68 (0.94-2.99) | .078 |
| RIC vs MAC | 1.13 (0.67-1.93) | .64 | 0.84 (0.57-1.25) | .4 | 0.64 (0.37-1.09) | .1 |
| Female donor to male recipient | 0.75 (0.39-1.45) | .39 | 1.46 (0.98-2.2) | .066 | 1.67 (0.96-2.92) | .07 |
| Patient CMV pos. | 0.98 (0.52-1.84) | .94 | 0.71 (0.46-1.1) | .13 | 0.63 (0.36-1.11) | .11 |
| Donor CMV pos. | 1 (0.57-1.74) | 1 | 1.22 (0.81-1.81) | .34 | 0.83 (0.48-1.42) | .49 |
| Year of HCT | 0.98 (0.89-1.07) | .63 | 0.99 (0.92-1.06) | .73 | 0.98 (0.89-1.09) | .71 |
BM, bone marrow; 95% CI, 95% confidence interval; RIC, reduced intensity conditioning; PBSC, peripheral blood stem cells; pos., positive.